NVS
Novartis AG
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Market Cap: 225 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE INC.
Website: https://www.novartis.com/
Shares Outstanding: 2.28 Billion
Float: 0
Dividend: 3.369942861240267 (0.03%)
Beta: 0.3517714231333563
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2374 trading days
From: 2015-07-20 To: 2024-01-04
Lowest Point:
Novartis Makes Substantial Pipeline Progress On A Couple Of Fronts
via: SeekingAlpha at 2019-06-13 06:52:07:000
Novartis ( NVS ) announced that it had successfully completed a phase 3 study treating patients with asthma using QMF149. These positive phase 3 results show that the company has a good chance at achieving European approval for this drug. Even QVM149, another asthma treatment, is up for Eu… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Value Hunting: ADRs Earning Top Quality Scores
via: SeekingAlpha at 2019-06-12 05:33:18:000
Source: CNN. Background As the Warren Buffett Indicator keeps flirting with the all-time high (see below), long-term value/quality-focused investors in the U.S. may want to reduce their home-country bias a bit by looking overseas in order to expand the investable universe. Source: G… read more...
Novartis' Cosentyx shows sustained benefit in late-stage psoriatic arthritis study
via: SeekingAlpha at 2019-06-12 03:24:15:000
New data from a Phase 3 clinical trial, FUTURE 5 , evaluating Novartis' (NYSE: NVS ) Cosentyx (secukinumab) in adults with active psoriatic arthritis (PsA) showed a durable treatment effect. The results are being presented at EULAR in Madrid. More news on: Novartis AG, Healthcare stock… read more...
Novartis Kisqali Might Have A Path Forward To Take On Pfizer's Ibrance
via: SeekingAlpha at 2019-06-11 16:14:01:000
Novartis ( NVS ) announced positive results from its phase 3 study using its cancer drug Kisqali to treat patients with HER+/HER2- advanced breast cancer. The study showed that treatment with Kisqali extends survival for these patients. These results were presented as a late-breaker at the… read more...
bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo
via: SeekingAlpha at 2019-06-11 14:08:42:000
bluebird bio ( BLUE ) announced that it had received European approval for its gene therapy Zynteglo to treat patients with beta-thalassemia. This was the first approval for the biotech which was an important milestone to reach. However, this is only the beginning. That's because bluebird bi… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2020-03-03 | 2020-03-12 | 2020-03-04 | 2020-01-31 | 3.0424917 | Cash | |||
| 2021-03-04 | 2021-03-15 | 2021-03-05 | 2021-01-26 | 3.37838 | Cash | |||
| 2022-03-08 | 2022-03-17 | 2022-03-09 | 2022-02-03 | 3.35745 | Cash | |||
| 2023-03-09 | 2023-03-20 | 2023-03-10 | 2023-02-02 | 3.46936 | Cash | |||
| 2024-03-07 | 2024-03-08 | 2024-02-12 | 3.77721 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|